Allarity Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ALLR Nasdaq 2836 www.allarity.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allarity Therapeutics, Inc.

Allarity CEO says 2026 represents an ‘inflection point’ - Jan 1st, 2026 6:05 am
Allarity Therapeutics Issues 2025 End of Year CEO Letter to Shareholders - Dec 31st, 2025 6:00 am
Allarity Therapeutics Provides Third Quarter 2025 Financial Results and Provides Business Updates - Nov 14th, 2025 7:00 am
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months - Sep 22nd, 2025 6:00 am
Allarity Therapeutics CEO to Present at Biomarkers & Precision Medicine 2025 - Sep 17th, 2025 6:00 am
Sector Update: Health Care Stocks Higher Late Afternoon - Aug 26th, 2025 1:51 pm
BC-Most Active Stocks - Aug 26th, 2025 8:30 am
Allarity Therapeutics Granted FDA Fast Track Designation for Stenoparib for the Treatment of Advanced Ovarian Cancer - Aug 26th, 2025 6:00 am
Allarity Therapeutics Provides Second Quarter 2025 Update, Highlighting Clinical Progress, IP Expansion, and New Partnerships - Aug 15th, 2025 2:30 pm
Allarity Therapeutics Announces New Licensing and Laboratory Services Agreement to Expand DRP® Platform Utilization - Jul 15th, 2025 6:00 am
Allarity Therapeutics Announces Appointment of Jeff Ervin as Chief Financial Officer - Jul 7th, 2025 6:00 am
Allarity Therapeutics Receives Australian Patent Acceptance Notice for Stenoparib DRP® Companion Diagnostic - Jun 30th, 2025 6:00 am
Allarity Therapeutics Announces Dosing of Second Patient in New Phase 2 Trial of Stenoparib in Advanced Ovarian Cancer - Jun 27th, 2025 6:00 am
Allarity Therapeutics Announces Changes to Board of Directors - Jun 11th, 2025 2:05 pm
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action - Jun 4th, 2025 6:00 am
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer - Jun 2nd, 2025 6:00 am
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US - May 12th, 2025 6:00 am
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment - May 9th, 2025 2:05 pm
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025 - Apr 25th, 2025 6:00 am
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update - Mar 31st, 2025 2:05 pm